RSV-neutralizing responses are thought to play a central role in preventing RSV infection. Therefore, the breadth of RSVPreF3-AS01鈥揺licited neutralization responses may contribute to vaccine efficacy against contemporary RSV strains and those that may emerge in the future....
观察到的不良事件通常是轻度至中度和短暂的,最常见的是注射部位疼痛、疲劳、肌痛和头痛。 原文出处:GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA 注:以上资讯来源于网络,由香港济民药业整理...
原文出处:GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
原文出处:GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
原文出处:GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动态,仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师...
原文出处:Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV) 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律...
原文出处:GSK marketing authorisation application for respiratory syncytial virus older adult vaccine candidate accepted by European Medicines Agency under accelerated assessment 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或...
[2]F Schwarz T, Hwang SJ, Ylisastigui P, et al. Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial. J Infect Dis. Published online December 14, 2023. doi:10.1093/infdis/jiad546...
该试验的安全性正受到密切监控,安全数据将由内部和外部独立数据监控委员会持续审查。 原文出处:GSK marketing authorisation application for respiratory syncytial virus older adult vaccine candidate accepted by European Medicines Agency under accelerated assessment...
We aimed to estimate the RSV burden and impact of adjuvanted RSV prefusion F protein vaccine (RSVPreF3) vaccination in OA in 6 countries; Argentina, Brazil, Chile, Colombia, Mexico, Panama.Methods: A static multi-cohort Markov model was used to estimate RSV-related outcomes over a 3-year ...